Boston Scientific (BSX) Reports Positive Outcomes From Prospective Study of Bronchial Thermoplasty in PAS2

May 24, 2017 9:19 AM EDT Send to a Friend
Boston Scientific (NYSE: BSX) today announced positive results from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login